RevMab

anti-BRAF (human), Rabbit Monoclonal (RM308)

CHF 459.00
In stock
REV-31-1194-00-R100100 µlCHF 459.00
More Information
Product Details
Synonyms Proto-oncogene B-Raf; p94; v-Raf Murine Sarcoma Viral Oncogene Homolog B1; Serine/threonine-protein Kinase B-raf
Product Type Recombinant Antibody
Properties
Clone RM308
Isotype Rabbit IgG
Source/Host Rabbit
Immunogen/Antigen A peptide corresponding to the residues near N-terminus of human B-raf.
Application

Immunohistochemistry (IHC): 1:200-1:500 dilution
Western Blot (WB): 1:100-1:200 dilution

Crossreactivity Human
Specificity

This antibody reacts to human serine/threonine-protein kinase B-raf (BRAF). It may also react to mouse B-raf, as predicted by immunogen homology.

Purity Protein A purified.
Purity Detail Protein A affinity purified from an animal origin-free culture supernatant.
Concentration N/A
Formulation Liquid. 50% Glycerol/PBS with 1% BSA and 0.09% sodium azide.
Isotype Negative Control

Rabbit IgG

Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

Accession Number P15056
Declaration Manufactured by RevMab Biosciences.
Shipping and Handling
Shipping BLUE ICE
Long Term Storage -20°C
Handling Advice Avoid freeze/thaw cycles.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Description

BRAF is a human gene that encodes a protein called B-Raf. B-Raf is a member of the Raf kinase family of growth signal transduction protein kinases. This protein plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation and secretion. Mutations in the BRAF gene can cause birth defects (inherited) or cancer, as an oncogene. Mutations in this gene have been found in cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, papillary thyroid carcinoma, non-small-cell lung carcinoma, adenocarcinoma of the lung, brain tumors including glioblastoma and Pleomorphic Xanthoastrocytomas as well as inflammatory diseases like erdheim-chester disease. The majority (>90%) of BRAF mutant cancers harbor the V600E mutation. The mutation leads to activation of the MAPK signaling pathway that increases cell invasion and reduces apoptosis. It also leads to reduced expression of melanocyte differentiation antigens and subsequent immune evasion

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.